Herceptin and Tykerb effective against a subset of gastric cancers
March 1, 2010 by admin · Leave a Comment
Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
A combination of two targeted therapies already shown to be effective in breast cancer packs an effective one-two punch against a subset of gastric cancers that have a specific genetic mutation, a study at UCLA’s Jonsson Comprehensive Cancer Center has found.
Team finds link between stomach-cancer bug and cancer-promoting factor
January 5, 2010 by admin · Leave a Comment
Contact: Diana Yates
diya@illinois.edu
217-333-5802
University of Illinois at Urbana-Champaign
CHAMPAIGN, lll. Researchers report that Helicobacter pylori, the only bacterium known to survive in the harsh environment of the human stomach, directly activates an enzyme in host cells that has been associated with several types of cancer, including gastric cancer.
Does Helicobacter pylori eradication therapy prevent gastric cancer?
September 25, 2009 by admin · Leave a Comment
Although it has been demonstrated that Helicobacter pylori causes gastric cancer, it is still controversial that whether H. pylori eradication therapy is effective in primary prevention of gastric cancer. This is especially important for Yamagata Prefecture, a region of Japan with the second highest incidence of gastric cancer in the world.
A breakthrough in gastric carcinogenesis
June 11, 2009 by admin · Leave a Comment
Checkpoint with forkhead and ring finger (CHFR) is a mitotic stress checkpoint gene whose promoter is frequently methylated in various kinds of cancer. In gastric cancer, CHFR promoter hypermethylation has been reported to lead to chromosome instability (CIN) and genetic instability is one of the hallmarks of human cancer.
New minimally invasive surgery option for patients with stomach cancer
April 16, 2009 by admin · Leave a Comment
A novel, minimally invasive surgical approach to treat stomach cancer has been shown to have advantages that may make it a preferable treatment for some patients.
A new study led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) compares traditional “open” surgery to remove the stomach with laparoscopic gastrectomy a minimally invasive procedure in which the surgeon removes the stomach while guided by a magnified image projected by a thin, lighted tube with a video camera at its tip, called a laparoscope. The findings demonstrate that while laparoscopic surgeries generally took longer to perform than open procedures, the minimally invasive approach yielded shorter hospital stays, decreased need for postoperative pain relief, fewer complications after surgery, and similar rates of recurrence-free survival after 36 months of follow-up.
Broccoli sprouts may protect against stomach cancer and ulcers
April 6, 2009 by admin · Leave a Comment
A small, pilot study in 50 people in Japan suggests that eating two and a half ounces of broccoli sprouts daily for two months may confer some protection against a rampant stomach bug that causes gastritis, ulcers and even stomach cancer.Citing their new “demonstration of principle” study, a Johns Hopkins researcher and an international team of scientists caution that eating sprouts containing sulforaphane did not cure infection by the bacterium Helicobacter pylori (H. pylori). They do not suggest that eating this or any amount of broccoli sprouts will protect anyone from stomach cancer or cure GI diseases.
A new light shed on tumor immunotherapy for gastric cancer
December 23, 2008 by admin · Leave a Comment
Dendritic cells (DCs) are professional antigen presenting cells (APCs) that both initiate and modulate the immune response. DCs are cells in the pathway of antigen capture and presentation to T cells, with the unique ability to directly prime nave CD4+ and CD8+ T cells. Gastric cancer is one of the most common cancers. Although gastric cancer therapy has made great progress, it is still difficult to treat advanced gastric cancer, as it has spread to the lymph glands and metastasized. Currently, tumor immunotherapy for gastric cancer has potential. DCs are believed to be essential for stimulating tumor-specific cytotoxic T lymphocyte (CTL) and inducing the protective and therapeutic anti-tumor immunity.
Researchers describe how chronic inflammation can lead to stomach cancer
November 6, 2008 by admin · Leave a Comment
A multi-center research team, led by Columbia University Medical Center, has uncovered a major contributor to the cause of stomach cancer the second leading cause of cancer-related mortality in the world. The team described for the first time, that elevated levels of a single proinflammatory cytokine, an immune system protein called interleukin-1 beta (IL-1â), can start the progression towards stomach cancer. These results are published in the Nov. 4, 2008 issue of Cancer Cell. The researchers hope to use this finding to develop ways to block this process, thereby preventing cancer from developing.
Early treatment of stomach infection may prevent cancer
May 1, 2008 by admin · Leave a Comment
Based on research using a new mouse model of gastritis and stomach cancer, researchers from the Massachusetts Institute of Technology (MIT) say that prompt treatment of Helicobacter pylori (H. pylori) infections reverses damage to the lining of the stomach that can lead to cancer.
Stomach cancer to fall 25% in a decade
August 16, 2007 by admin · Leave a Comment
Filed under: Stomach Cancer, Research
According to a new study from the Netherlands, new cases of stomach cancer are expected to drop off by as much as 25% in the next decade in Europe. The reason? Better living conditions.
